 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of angioedema?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes LORAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes LORAZEPAM increase or decrease the risk of angioedema?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"LORAZEPAM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse reactions to benzodiazepines, including CNS effects and respiratory depression, are dose dependent, with more severe effects [0m
[31moccurring with high doses. In a sample of about [0m[1;31m3500[0m[31m patients treated for anxiety, the most frequent adverse reaction to lorazepam was sedation [0m[1;31m([0m[1;31m15.9[0m[31m%[0m[1;31m)[0m[31m, followed by dizziness [0m[1;31m([0m[1;31m6.9[0m[31m%[0m[1;31m)[0m[31m, weakness [0m[1;31m([0m[1;31m4.2[0m[31m%[0m[1;31m)[0m[31m, [0m
[31mand unsteadiness [0m[1;31m([0m[1;31m3.4[0m[31m%[0m[1;31m)[0m[31m. The incidence of sedation and unsteadiness increased with age. LORAZEPAM: adverse_reactions: Other adverse reactions to benzodiazepines, including lorazepam are fatigue, [0m
[31mdrowsiness, amnesia, memory impairment, confusion, disorientation, depression, unmasking of depression, disinhibition, euphoria, suicidal ideation/attempt, ataxia, asthenia, extrapyramidal symptoms, [0m
[31mconvulsions/seizures, tremor, vertigo, eye function/visual disturbance [0m[1;31m([0m[31mincluding diplopia and blurred vision[0m[1;31m)[0m[31m, dysarthria/slurred speech, change in libido, impotence, decreased orgasm; headache, [0m
[31mcoma; respiratory depression, apnea, worsening of sleep apnea, worsening of obstructive pulmonary disease; gastrointestinal symptoms including nausea, change in appetite, constipation, jaundice, [0m
[31mincrease in bilirubin, increase in liver transaminases, increase in alkaline phosphatase; hypersensitivity reactions, anaphylactoid reactions; dermatological symptoms, allergic skin reactions, [0m
[31malopecia; syndrome of inappropriate antidiuretic LORAZEPAM: adverse_reactions: hormone [0m[1;31m([0m[31mSIADH[0m[1;31m)[0m[31m, hyponatremia; thrombocytopenia, agranulocytosis, pancytopenia; hypothermia; and autonomic [0m
[31mmanifestations. Paradoxical reactions, including anxiety, excitation, agitation, hostility, aggression, rage, sleep disturbances/insomnia, sexual arousal, and hallucinations may occur. Small decreases[0m
[31min blood pressure and hypotension may occur but are usually not clinically significant, probably being related to the relief of anxiety produced by lorazepam. To report SUSPECTED ADVERSE REACTIONS, [0m
[31mcontact Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: pregnancy: Although early studies reported an increased risk of congenital malformations with diazepam and chlordiazepoxide, there was no consistent pattern noted. In addition, the[0m
[31mmajority of more recent case-control and cohort studies of benzodiazepine use during pregnancy, which were adjusted for confounding exposures to alcohol, tobacco and other medications, have not [0m
[31mconfirmed these findings. Animal Data Reproductive studies in animals were performed in mice, rats, and two strains of rabbits. Occasional anomalies [0m[1;31m([0m[31mreduction of tarsals, tibia, metatarsals, [0m
[31mmalrotated limbs, gastroschisis, malformed skull, and microphthalmia[0m[1;31m)[0m[31m were seen in drug-treated rabbits without relationship to dosage. Although all of these anomalies were not present in the [0m
[31mconcurrent control group, they have been reported to occur randomly in historical controls. At doses of [0m[1;31m40[0m[31m mg/kg and higher, there was evidence of fetal resorption and increased fetal loss in rabbits [0m
[31mwhich was not seen at lower doses. LORAZEPAM: precautions: Nursing Mothers Risk Summary Lorazepam is present in breast milk. There are reports of sedation, poor feeding and poor weight gain in infants[0m
[31mexposed to benzodiazepines through breast milk. The effects of lorazepam on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the [0m
[31mmotherâ€™s clinical need for lorazepam and any potential adverse effects on the breastfed infant from lorazepam or from the underlying maternal condition. Clinical Considerations Infants exposed to [0m
[31mlorazepam through breast milk should be monitored for sedation, poor feeding and poor weight gain. Geriatric Use Clinical studies of lorazepam generally were not adequate to determine whether subjects[0m
[31maged [0m[1;31m65[0m[31m and over respond differently than younger subjects; however, the incidence of sedation and unsteadiness was observed to increase with age [0m[1;31m([0m[31msee ADVERSE REACTIONS [0m[1;31m)[0m[31m. Age does not appear to have [0m
[31ma significant effect on lorazepam kinetics [0m[1;31m([0m[31msee CLINICAL PHARMACOLOGY [0m[1;31m)[0m[31m. LORAZEPAM: precautions: Clinical circumstances, some of which may be more common in the elderly, such as hepatic or renal [0m
[31mimpairment, should be considered. Greater sensitivity [0m[1;31m([0m[31me.g., sedation[0m[1;31m)[0m[31m of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, and lower [0m
[31mdoses may be sufficient in these patients [0m[1;31m([0m[31msee DOSAGE AND ADMINISTRATION [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: pharm_class_cs         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: openfda: spl_id         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: drug_interactions: Drug Interactions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites [0m
[31min the CNS that control respiration. Benzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. When benzodiazepines and opioids are combined, the potential for [0m
[31mbenzodiazepines to significantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for [0m
[31mrespiratory depression and sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, [0m
[31mantipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. LORAZEPAM: drug_interactions: Concomitant use of [0m
[31mclozapine and lorazepam may produce marked sedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in [0m
[31mincreased plasma concentrations and reduced clearance of lorazepam. Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam [0m
[31mwith probenecid may result in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% [0m
[31mwhen coadministered with probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the [0m
[31msedative effects of benzodiazepines, including lorazepam.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: precautions: Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lorazepam during pregnancy [0m[1;31m([0m[31msee PRECAUTIONS: Pregnancy[0m
[1;31m)[0m[31m. Nursing Instruct patients to notify their healthcare provider if they are breastfeeding or intend to breastfeed. Instruct breastfeeding patients using lorazepam to monitor infants for excessive [0m
[31msedation, poor feeding and poor weight gain, and to seek medical attention if they notice these signs [0m[1;31m([0m[31msee PRECAUTIONS: Nursing Mothers [0m[1;31m)[0m[31m. Essential Laboratory Tests Some patients on lorazepam have [0m
[31mdeveloped leukopenia, and some have had elevations of LDH. As with other benzodiazepines, periodic blood counts and liver function tests are recommended for patients on long-term therapy. Drug [0m
[31mInteractions The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration. [0m
[31mBenzodiazepines interact at GABA A sites and opioids interact primarily at mu receptors. LORAZEPAM: precautions: When benzodiazepines and opioids are combined, the potential for benzodiazepines to [0m
[31msignificantly worsen opioid-related respiratory depression exists. Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression [0m
[31mand sedation. The benzodiazepines, including lorazepam, produce increased CNS-depressant effects when administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, [0m
[31msedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. Concomitant use of clozapine and lorazepam may produce marked [0m
[31msedation, excessive salivation, hypotension, ataxia, delirium, and respiratory arrest. Concurrent administration of lorazepam with valproate results in increased plasma concentrations and reduced [0m
[31mclearance of lorazepam. LORAZEPAM: precautions: Lorazepam dosage should be reduced to approximately [0m[1;31m50[0m[31m% when coadministered with valproate. Concurrent administration of lorazepam with probenecid may [0m
[31mresult in a more rapid onset or prolonged effect of lorazepam due to increased half-life and decreased total clearance. Lorazepam dosage needs to be reduced by approximately [0m[1;31m50[0m[31m% when coadministered [0m
[31mwith probenecid. The effects of probenecid and valproate on lorazepam may be due to inhibition of glucuronidation. Administration of theophylline or aminophylline may reduce the sedative effects of [0m
[31mbenzodiazepines, including lorazepam. Carcinogenesis and Mutagenesis No evidence of carcinogenic potential emerged in rats during an [0m[1;31m18[0m[31m-month study with lorazepam. No studies regarding mutagenesis [0m
[31mhave been performed. LORAZEPAM: pregnancy: Pregnancy Pregnancy Exposure Registry There is a pregnancy registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including [0m
[31mlorazepam, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Psychiatric Medications at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m961[0m[31m-[0m[1;31m2388[0m[31m or visiting online at [0m
[4;31mhttps://womensmentalhealth.org/pregnancyregistry/.[0m[31m Risk Summary Neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal [0m
[31mwithdrawal [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome and Clinical Considerations [0m[1;31m)[0m[31m. Available data from published observational studies of pregnant women exposed to benzodiazepines do [0m
[31mnot report a clear association with benzodiazepines and major birth defects [0m[1;31m([0m[31msee Data[0m[1;31m)[0m[31m . The background risk of major birth defects and miscarriage for the indicated population is unknown. All [0m
[31mpregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. LORAZEPAM: pregnancy: general population, the estimated risk of major birth defects and of miscarriage [0m
[31min clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions Benzodiazepines cross the placenta and may produce respiratory [0m
[31mdepression, hypotonia and sedation in neonates. Monitor neonates exposed to lorazepam during pregnancy or labor for signs of sedation, respiratory depression, hypotonia, and feeding problems. Monitor [0m
[31mneonates exposed to lorazepam during pregnancy for signs of withdrawal. Manage these neonates accordingly [0m[1;31m([0m[31msee WARNINGS: Neonatal Sedation and Withdrawal Syndrome [0m[1;31m)[0m[31m. Data Human Data Published data [0m
[31mfrom observational studies on the use of benzodiazepines during pregnancy do not report a clear association with benzodiazepines and major birth defects.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: warnings: WARNINGS Risks from Concomitant Use with Opioids Concomitant use of benzodiazepines, including lorazepam, and opioids may result in profound sedation, respiratory [0m
[31mdepression, coma, and death. Because of these risks, reserve concomitant prescribing of these drugs in patients for whom alternative treatment options are inadequate. Observational studies have [0m
[31mdemonstrated that concomitant use of opioid analgesics and benzodiazepines increases the risk of drug-related mortality compared to use of opioids alone. If a decision is made to prescribe lorazepam [0m
[31mconcomitantly with opioids, prescribe the lowest effective dosages and minimum durations of concomitant use, and follow patients closely for signs and symptoms of respiratory depression and sedation. [0m
[31mIn patients already receiving an opioid analgesic, prescribe a lower initial dose of lorazepam than indicated in the absence of an opioid and titrate based on clinical response. LORAZEPAM: warnings: [0m
[31mIf an opioid is initiated in a patient already taking lorazepam, prescribe a lower initial dose of the opioid and titrate based upon clinical response. Advise both patients and caregivers about the [0m
[31mrisks of respiratory depression and sedation when lorazepam is used with opioids. Advise patients not to drive or operate heavy machinery until the effects of concomitant use with the opioid have been[0m
[31mdetermined [0m[1;31m([0m[31msee PRECAUTIONS: Drug Interactions [0m[1;31m)[0m[31m. Abuse, Misuse, and Addiction The use of benzodiazepines, including lorazepam, exposes users to the risks of abuse, misuse, and addiction, which can [0m
[31mlead to overdose or death. LORAZEPAM: warnings: Abuse and misuse of benzodiazepines often [0m[1;31m([0m[31mbut not always[0m[1;31m)[0m[31m involve the use of doses greater than the maximum recommended dosage and commonly involve [0m
[31mconcomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or [0m
[31mdeath [0m[1;31m([0m[31msee DRUG ABUSE AND DEPENDENCE: Abuse [0m[1;31m)[0m[31m. Before prescribing lorazepam and throughout treatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31me.g., using a standardized screening [0m
[31mtool[0m[1;31m)[0m[31m. Use of lorazepam, particularly in patients at elevated risk, necessitates counseling about the risks and proper use of lorazepam along with monitoring for signs and symptoms of abuse, misuse, [0m
[31mand addiction. Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction [0m[1;31m([0m[31me.g.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: boxed_warning: WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS â€¢ Concomitant use of benzodiazepines and [0m
[31mopioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. [0m
[31mLimit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [0m[1;31m([0m[31msee WARNINGS and PRECAUTIONS [0m[1;31m)[0m[31m. â€¢ The use of benzodiazepines, [0m
[31mincluding lorazepam, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other [0m
[31mmedications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. LORAZEPAM: boxed_warning: Before prescribing lorazepam and throughout [0m
[31mtreatment, assess each patientâ€™s risk for abuse, misuse, and addiction [0m[1;31m([0m[31msee WARNINGS [0m[1;31m)[0m[31m. â€¢ The continued use of benzodiazepines, including lorazepam, may lead to clinically significant physical [0m
[31mdependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Abrupt discontinuation or rapid dosage reduction of lorazepam after continued use may [0m
[31mprecipitate acute withdrawal reactions, which can be life-threatening. To reduce the risk of withdrawal reactions, use a gradual taper to discontinue lorazepam or reduce the dosage [0m[1;31m([0m[31m DOSAGE AND [0m
[31mADMINISTRATION and WARNINGS [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: spl_medguide: â€¢ Store lorazepam tablets in a tightly closed container at room temperature between [0m[1;31m20[0m[31mÂ° to [0m[1;31m25[0m[31mÂ°C [0m[1;31m([0m[1;31m68[0m[31mÂ° to [0m[1;31m77[0m[31mÂ°F[0m[1;31m)[0m[31m. â€¢ Keep lorazepam tablets and all medicines out of the [0m
[31mreach of children. General information about the safe and effective use of lorazepam tablets Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use [0m
[31mlorazepam tablets for a condition for which it was not prescribed. Do not give lorazepam tablets to other people, even if they have the same symptoms that you have. It may harm them. You can ask your [0m
[31mpharmacist or healthcare provider for information about lorazepam tablets that is written for health professionals. What are the ingredients in lorazepam tablets? Active ingredient: lorazepam Inactive[0m
[31mingredients: anhydrous lactose, magnesium stearate, microcrystalline cellulose, and polacrilin potassium. LORAZEPAM: spl_medguide: Distributed by: Aurobindo Pharma USA, Inc. [0m[1;31m279[0m[31m Princeton-Hightstown [0m
[31mRoad East Windsor, NJ [0m[1;31m08520[0m[31m Manufactured by: Aurobindo Pharma Limited Hyderabad-[0m[1;31m500[0m[31m [0m[1;31m032[0m[31m, India For more information, call Aurobindo Pharma USA, Inc. at [0m[1;31m1[0m[31m-[0m[1;31m866[0m[31m-[0m[1;31m850[0m[31m-[0m[1;31m2876[0m[31m. This Medication Guide has been [0m
[31mapproved by the U.S. Food and Drug Administration. Repackaged by Preferred Pharmaceuticals, Inc. LORAZEPAM: spl_medguide: Revised: [0m[1;31m06[0m[31m/[0m[1;31m2023[0m[31m         [0m
[31mSOURCE:LORAZEPAM label[0m


[31mCONTENT: LORAZEPAM: dosage_and_administration: DOSAGE AND ADMINISTRATION Lorazepam tablets are administered orally. For optimal results, dose, frequency of administration, and duration of therapy [0m
[31mshould be individualized according to patient response. To facilitate this, [0m[1;31m0.5[0m[31m mg, [0m[1;31m1[0m[31m mg, and [0m[1;31m2[0m[31m mg tablets are available. The usual range is [0m[1;31m2[0m[31m to [0m[1;31m6[0m[31m mg/day given in divided doses, the largest dose [0m
[31mbeing taken before bedtime, but the daily dosage may vary from [0m[1;31m1[0m[31m to [0m[1;31m10[0m[31m mg/day. For anxiety, most patients require an initial dose of [0m[1;31m2[0m[31m to [0m[1;31m3[0m[31m mg/day given two times a day or three times a day. For [0m
[31minsomnia due to anxiety or transient situational stress, a single daily dose of [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m mg may be given, usually at bedtime. For elderly or debilitated patients, an initial dosage of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mg/day in [0m
[31mdivided doses is recommended, to be adjusted as needed and tolerated. LORAZEPAM: dosage_and_administration: The dosage of lorazepam tablets should be increased gradually when needed to help avoid [0m
[31madverse effects. When higher dosage is indicated, the evening dose should be increased before the daytime doses. Discontinuation or Dosage Reduction of Lorazepam Tablets To reduce the risk of [0m
[31mwithdrawal reactions, use a gradual taper to discontinue lorazepam tablets or reduce the dosage. If a patient develops withdrawal reactions, consider pausing the taper or increasing the dosage to the [0m
[31mprevious tapered dosage level. Subsequently decrease the dosage more slowly [0m[1;31m([0m[31msee WARNINGS: Dependence and Withdrawal Reactions and DRUG ABUSE AND DEPENDENCE: Dependence [0m[1;31m)[0m[31m.         [0m
[31mSOURCE:LORAZEPAM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for lorazepam include various [0m
[32mCNS effects, respiratory depression, and other effects such as sedation, dizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction.[0m

[32mSOURCE: LORAZEPAM label[0m
[32mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[32m...[0m[32m autonomic manifestations.[0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: The available information from the LORAZEPAM label does not indicate [0m
[34mthat lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for lorazepam include various CNS effects, respiratory depression, and other effects such as sedation, [0m
[34mdizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction.[0m

[34mSOURCE: LORAZEPAM label[0m
[34mEXTRACT_START_END: LORAZEPAM: adverse_reactions: ADVERSE REACTIONS Most adverse[0m[34m...[0m[34m autonomic manifestations.[0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does LORAZEPAM increase or decrease the risk of angioedema?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of angioedema."[0m[32m,[0m
[32m      [0m[32m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for [0m
[32mlorazepam include various CNS effects, respiratory depression, and other effects such as sedation, dizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does LORAZEPAM increase or decrease the risk of angioedema?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether LORAZEPAM increases or decreases the risk of angioedema."[0m[34m,[0m
[34m      [0m[34m"FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for [0m
[34mlorazepam include various CNS effects, respiratory depression, and other effects such as sedation, dizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does LORAZEPAM increase or decrease the risk of angioedema?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether LORAZEPAM increases or decreases the risk of angioedema.[0m
[1;31m2[0m[31m. FDAHandler responded that the available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for [0m
[31mlorazepam include various CNS effects, respiratory depression, and other effects such as sedation, dizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction.[0m
[31m        -----[0m
[31m        Final answer: The available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning process appears to be sound. The user consulted FDAHandler for information on the relationship between LORAZEPAM and the risk of angioedema. The response from FDAHandler[0m
[32mindicated that the LORAZEPAM label does not mention angioedema as a known adverse reaction. Therefore, the conclusion that the available information does not indicate an increase or decrease in the [0m
[32mrisk of angioedema due to LORAZEPAM is based on the absence of such information in the label, which is a valid reasoning process given the context provided. There are no apparent flaws in the [0m
[32mreasoning provided."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning process appears to be sound. The user consulted FDAHandler for information on the relationship between LORAZEPAM and the risk of angioedema. The response from FDAHandler[0m
[34mindicated that the LORAZEPAM label does not mention angioedema as a known adverse reaction. Therefore, the conclusion that the available information does not indicate an increase or decrease in the [0m
[34mrisk of angioedema due to LORAZEPAM is based on the absence of such information in the label, which is a valid reasoning process given the context provided. There are no apparent flaws in the [0m
[34mreasoning provided."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning process appears to be sound. The user consulted FDAHandler for information on the relationship between LORAZEPAM and the risk of angioedema. The response from [0m
[31mFDAHandler indicated that the LORAZEPAM label does not mention angioedema as a known adverse reaction. Therefore, the conclusion that the available information does not indicate an increase or [0m
[31mdecrease in the risk of angioedema due to LORAZEPAM is based on the absence of such information in the label, which is a valid reasoning process given the context provided. There are no apparent flaws[0m
[31min the reasoning provided.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-angioedema-LORAZEPAM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mThe available information from the LORAZEPAM label does not indicate that lorazepam increases or decreases the risk of angioedema. The adverse reactions listed for lorazepam include various CNS [0m
[32meffects, respiratory depression, and other effects such as sedation, dizziness, weakness, and unsteadiness, but angioedema is not mentioned as a known adverse reaction.[0m
